Dapagliflozin is widely accepted as an effective drug for patients with diabetes as evidenced by the clinical trials. The economic evaluation of the drug is shadowed by the potential of the drug in managing diabetes. A study conducted by McEwan et al analyzed the cost-effectiveness of dapagliflozin in treating high risk patients with type 2 diabetes (T2DM), utilizing both directly observed events in the DECLARE-TIMI 58 trial and substitute risk factors to predict outcomes not explored in the trial.

      The UK based study collated survival curves derived from the DECLARE‐TIMI 58 trial, and extrapolated over a lifetime for all-cause mortality, hospitalization for heart failure, stroke, myocardial infarction, unstable angina, and end-stage kidney disease. The economic analysis included the overall DECLARE trial population and reported patient subgroups.

      The study outcomes demonstrate that in the comparative analysis between dapagliflozin and placebo, dapagliflozin appears to be cost-effective, while considering evidence reported from the DECLARE-TIMI 58 trial. The findings project the potential of dapagliflozin to have a significant impact in reducing the economic burden of T2DM and its associated complications across a wide spectrum of patients with type 2 diabetes.